Joseph Hymas, MD
Interventional Cardiology · Twin Falls, IDNPI 1942490578
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Medtronic at 51.3% of the total. Reporting peaked in 2022 at $828 and has fallen 81.9% since, to $150 in 2025. That places this record below the midpoint for interventional cardiology clinicians in ID, where the typical reported total is $3,406.
Across 73 payments — averaging $34.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$666
- Pfizer$159
- Johnson & Johnson$64
- Amgen$63
- AstraZeneca$56
- plus $230 from 9 others
What the payments were for
- Travel & lodging$1,19347%
- Food & beverage$1,34953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 15 | $1,305 |
| Boston Scientific | 24 | $666 |
| Pfizer | 11 | $159 |
| Johnson & Johnson | 4 | $64 |
| Amgen | 3 | $63 |
| AstraZeneca | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Abiomed | 2 | $44 |
| Novartis | 2 | $24 |
| Abbott | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Shockwave Medical, Inc | 1 | $21 |
| United Therapeutics Corporation | 1 | $19 |
| Turn-key Medical, Inc. | 1 | $16 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,096
How this compares
$2,543 in reported general payments places this provider in the 30th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $303,265 |
| XareltoRivaroxaban | 98 | $84,764 |
| FarxigaDapagliflozin Propanediol | 28 | $28,302 |
| Repatha SureclickEvolocumab | 15 | $16,661 |
| Metoprolol Succinate | 515 | $6,653 |
| Praluent PenAlirocumab | 12 | $5,693 |
| Atorvastatin Calcium | 336 | $4,282 |
| Flecainide Acetate | 68 | $3,892 |
| ClopidogrelClopidogrel Bisulfate | 208 | $2,660 |
| Potassium Chloride | 77 | $1,857 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $1,618 |
| SotalolSotalol Hcl | 63 | $1,524 |
| Carvedilol | 154 | $1,398 |
| Metoprolol Tartrate | 155 | $1,346 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 113 | $1,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $303,265323 claims |
| Johnson & JohnsonXarelto | $64 | $84,76498 claims |
| AstraZenecaFarxiga | $56 | $28,30228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Twin Falls
- Robert TonksTwin Falls$3K
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Kendra CoonseBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Andrew MichaelsNampa$7K
- George SamaanNampa$6K
- Ryley McPetersNampa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.